Positive data for Acesion’s atrial fibrillation candidates
The company intends to advance AF drugs that address current risk concerns with existing therapies
Read More
Tag: acesion
Acesion announces positive atrial fibrillation study
Candidate AP30663 is an inhibitor for the conversion of atrial fibrillation to a normal sinus rhythm
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
